Home > RegMed Daily Closing Bell > FB is a lottery ticket but, SC (stem cells) can save lives

FB is a lottery ticket but, SC (stem cells) can save lives

  End of Day, Cause and Effect

  

EOD Commentary: RegMed stocks moved deeper into negative territory, Friday in volatile trading across the board.  . The VIX surged to stay up at … 23 from 22. How many times and ways to reiterate the … current … news … RegMed stocks had been invisible as FB, macro concerns blocked out the universe’s up-tick from Health Canada approval of Osiris’ (OSIR) Prochymal.

 

Back to FB … “Anyone chasing any hot, big IPO is taking a significant risk; while it’s good for … some people … some of the time, when you buy a lottery ticket, it doesn’t always win”. What is different from the RegMed universe … change seats …? Closed at $38.23 +0.23 or 0.61% … so much for all the hype!!

 

In the near-term, the absence of both average investors … threatens to topple the market even further off its early-April high. “Individual investors have been net sellers, measured by the flows of mutual funds that invest in US stocks”. And … they have been selling for 12 straight months!!

 

Closing Bell: The NASDAQ closed DOWN -34.90 (-1.24%) to 2,778.79. The Dow closed DOWN -73.11 (-0.49%) to 12,369.38.

 

Who is up … at the close:

  • Advanced Cell Technology (OTC BB: ACTC) +$0.0099 <+13.66%> to $0.0824;
  • BioMimetic (BMTI) +$0.01 <+0.43%> to $2.31;
  • BioTime (Amex: BTX) +$0.18 <+4.69%> to $4.02;
  • Cryo-Cell (OTC BB: CCEL) +$0.24 <+10.86%> to $2.45;
  • Cytori (CYTX) +$0.01 <+0.49%> to $2.05;
  • NeoStem (Amex: NBS) +$0.013 <+3.71%> to $0.355;
  • Neuralstem (Amex: CUR) +$0.007 <+0.77%> to $0.906;
  • Osiris (OSIR) +$0.29 <+5.51%> to $5.55.

                                                                             

 

 

 

 

 

 

 

 

 

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • StumbleUpon
  • Reddit
  • Facebook
  • LinkedIn
  • TwitThis
  1. No comments yet.
  1. No trackbacks yet.